Investors should consider Micron Technology (MU) as a high-conviction "buy the dip" opportunity, with potential earnings reaching $34-$43 per share by 2027 as it challenges NVIDIA (NVDA) for net income dominance. While the broader semiconductor sector has faced technical liquidations, Hynix remains a recommended safe haven for those seeking direct exposure to High Bandwidth Memory. Avoid Intuitive Surgical (ISRG) and Abbott Laboratories (ABT) at current levels, as their valuations remain unattractive despite recent price drops. In the biotech space, exercise extreme caution with 10x Genomics (TXG) ahead of its August Phase 3 data, as the options market is currently pricing in a high probability of failure. For long-term growth, prioritize major tech leaders like Apple, Amazon, and Alphabet following recent market volatility, as fundamental value is expected to prevail over temporary price dips.

Micron Technology (MU)

• Shkreli presents a highly bullish case for Micron, suggesting it is currently in a "special situation" regarding its valuation and earnings potential.
• Financial Projections:
  • Estimates that the company could generate $200 billion to $250 billion in earnings through calendar 2027.
  • Argues that the street is being conservative; Shkreli projects $34-$43 in earnings per share (EPS) over the coming quarters, slightly above consensus.
  • Claims Micron is on a "crash course" to potentially match or exceed NVIDIA's net income in the near future.
• Valuation:
  • At a $675 billion enterprise value, the stock trades at roughly 3x 2028 enterprise value based on his aggressive earnings projections.
  • Even in a "trough" or mid-cycle scenario where revenue drops 50%, he estimates the stock would trade at 6x earnings, which he considers very attractive.
• Market Dynamics:
  • Notes that while DRAM is "relatively easy to make," supply is constrained until 2030.
  • Attributes recent price drops to "liquidation and leverage" rather than fundamental issues.

Takeaways

• Bullish Sentiment: Shkreli views the current price as a "buy the dip" opportunity, suggesting the "memory fake out" is over and weak hands have been shaken out.
• Risk Factor: The primary threat is a potential "cratering" of RAM prices or a massive softening of demand, though he believes this is already partially priced in.
• Actionable Insight: Look for a "bullish ride" going into Q2; he views Micron as a superior value play compared to more expensive AI names.

Intuitive Surgical (ISRG)

• The stock saw a significant drop (down 10%) during the discussion.
• Shkreli expressed a lack of conviction, noting he hasn't looked at medical devices in a long time.
• He criticized the company for not moving into the Neuralink (Brain-Computer Interface) space, calling the management "retarded" for missing that opportunity.

Takeaways

• Bearish/Neutral Sentiment: Despite the large drop, Shkreli explicitly stated, "I'm going to avoid Intuitive. Could even be a short."
• Actionable Insight: He does not recommend buying this specific dip, as he does not find the valuation "cheap" even after the 10% decline.

Abbott Laboratories (ABT)

• Shkreli reviewed the company's diversified divisions, noting that Cardio and Diabetes (approx. 20% of the business) are the primary growth drivers.
• Segment Analysis:
  • Nutritionals: Business is "bailing" or falling.
  • Pediatrics: Not a growth business anymore.
  • Rhythm Management/Vascular: Showing solid growth.

Takeaways

• Neutral Sentiment: He views Abbott as a "solid company" but is unwilling to pay 24x earnings for a "slow grower."
• Actionable Insight: Avoid at current valuations unless there is a significant price correction; the growth in MedTech is currently concentrated in cardiovascular products.

10x Genomics (TXG) / Biotech Mentions

• 10x Genomics: Shkreli is undecided on whether to go long or short ahead of their Phase 3 data (expected August). He expressed skepticism, noting he is "allergic to bullshit" regarding biotech trials.
• Abivax (ABVX): Mentioned rumors of the company looking for an acquirer, though he noted there have been many "false starts" with this stock.
• Exelixis (EXEL): Expressed a bearish outlook, calling it a "dog." He believes the market for their drug Cabo has peaked and is skeptical of their pipeline drug Zanza after a study failure.
• Moderna (MRNA): Shkreli mentioned he was previously short and called the trade "embarrassing," implying a move against his position.

Takeaways

• Actionable Insight: Be cautious with 10x Genomics heading into August; Shkreli suggests the options market is pricing in a high probability of trial failure.
• Actionable Insight: For Abivax, the lack of stock reaction to buyout rumors suggests the market is skeptical of the news.

Investment Themes & Sector Insights

Semiconductor & AI Sector

• NVIDIA (NVDA): Noted the stock was around $200 (likely referring to a post-split price or specific trading level) and down 4%. He remains focused on the competition between NVIDIA and Micron for net income dominance.
• Hynix: Described as a "safe haven" in the memory space due to its high exposure to HBM (High Bandwidth Memory).
• Sentiment: Shkreli believes the broader market panic is driven by technical liquidations rather than a fundamental shift in the AI/Semiconductor story.

Trading Philosophy

• Taking Losses: Shkreli emphasized the importance of "taking the L" (loss) quickly. He mentioned selling Inmune (INMB) at a loss because he "got sick of it."
• Market Perception: He argues that trading is 100% about perception. When stocks go down, investors "fear the worst," but the "reality prevails over time."
• Quantitative Shift: He believes traditional "equities guys" using Bloomberg terminals are being replaced by "Quant guys" who use homebrew software and data-driven strategies.

General Market Outlook

• Bullish on the Dip: Shkreli's overall tone was to "buy the dip" on major tech (Apple, Amazon, Alphabet) as he believes the "Flash Crash" or temporary dip is over once sellers are exhausted.
• Private Equity vs. Trading: He noted that his biggest wins have come from Private Equity (buying molecules for nothing that became worth billions) rather than daily trading.